BMS' Inrebic (fedratinib) Receives Health Canada's Approval for Patients with Myelofibrosis
Shots:
- The approval is based on JAKARTA and JAKARTA2 clinical trials. JAKARTA study involves assessing Inrebic (500mg) vs PBO for at least 6 cycles in 289 patients in patients with intermediate-2 or high-risk MF- post-polycythemia vera MF or post-essential thrombocythemia MF with splenomegaly and platelet count ≥50 x 109/L
- The P-II JAKARTA 2 study involves assessing of Inrebic (400mg- qd) in 97 patients prior exposed to ruxolitinib with a diagnosis of intermediate-1 with symptoms- intermediate-2 or high-risk MF- post-polycythemia vera MF or post-essential thrombocythemia MF with splenomegaly and platelet count ≥50 x 109/L.1
- The 1EPs of the studies is ≥35% reduction in the volume of spleen size at the end of Cycle 6. Inrebic is a JAK inhibitor and is the first new treatment for patients with myelofibrosis in nearly a decade
Ref: PRNewswire | Image: BMS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com